Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Introduction
Diabetic macular edema (DME) is a leading cause of blindness in the workingage population of most developed countries [1] . The Wisconsin Epidemiologic Study of Diabetic Retinopathy showed that the ten-year rate of developing DME in the US was 20.1% among Type I diabetics, 25.4% among insulin-dependent Type II diabetics, and 13.9% for non-insulin dependent Type II diabetics [2] . Nearly half of those developing DME will lose two or more lines of visual acuity within two years [3] .
Macular laser photocoagulation, which had traditionally been standard treatment for DME since the Early Treatment Diabetic Retinopathy Study (ETDRS), slows the rate of vision loss and helps stabilize vision, but has demonstrated only limited ability to restore lost vision [4] . Intravitreal medications targeted toward vascular endothelial growth factor (VEGF) have become first line therapy in DME patients. These medications bind VEGF, thereby decreasing angiogenesis and vascular permeability, causing regression of diabetic neovascularization and reduction in DME respectively [1, 5] . Several recent clinical trials suggest that these therapies are more effective for DME than laser therapy [6] [7] [8] [9] [10] [11] [12] [13] .
Pathophysiology of DME
Chronic hyperglycemia contributes to alterations in the structural and cellular components of retinal microvasculature. Early on, there is damage to the pericytes that are responsible for regulating capillary perfusion, which results in microaneurysm formation and impaired regulation of retinal blood flow [14] . Damage to endothelial cells that are responsible for maintaining the blood-retinal barrier allows for accumulation of extracellular fluid in the macula. There is also thickening of the capillary basement membrane and increased deposition of extracellular matrix components [1, 14, 15] . Over time, continued retinal microvasculature damage results in capillary nonperfusion and retinal ischemia, resulting in upregulation of angiogenic factors, such as vascular endothelial growth factor (VEGF) [5] .
VEGF plays a key role not only in angiogenesis, but also in vascular permeability [16] . There are several different VEGF isoforms due to the alternative splicing and forming the vessel walls [17] .
VEGF-A is a critical regulator of ocular angiogenesis and vascular permeability.
VEGF-A acts at VEGFR 1 and 2. VEGFR1 (fms-like tyrosine kinase-1) has both positive and negative angiogenic effects; VEGFR2 (fetal liver kinase-1 and kinase insert domaincontaining receptor) is the primary mediator of the mitogenic, angiogenic and vascular permeability effects of VEGF-A [16] . VEGF mediates angiogenesis by promoting endothelial cell (EC) migration, proliferation, and survival. VEGF also possesses inflammatory properties through its capacity to mediate microvascular permeability and increase adhesion of leukocytes. VEGF was found to stimulate expression of intracellular adhesion molecule -1 (ICAM-1) and vascular cell adhesion molecule -1 (VCAM-1) [18] , thus incorporating the inflammatory cascade, initiating early diabetic retinal leukocyte adhesion and aiding the development of diabetic vasculopathy.
Inflammation plays an important role in the pathogenesis of DME, in which there is upregulation of prostaglandins and other inflammatory mediators, such as tumor 5 necrosis factor-alpha, cyclooxegenase-2, and interleukin-6, interleukin-8, Pentraxin-3, and Monocyte chemotactic protein-1 (see Table 2 ). In diabetic patients, leukocytes are more rigid and a higher proportion than usual are activated; increased retinal leukostasis results in capillary non-perfusion, endothelial cell damage, and vascular leakage via generation of toxic superoxide radicals and proteolytic enzymes [19, 20] .
Bevacizumab for DME
Bevacizumab is a full-length (149 kDa) recombinant humanized monoclonal IgG1 antibody that binds all isoforms of VEGF-A [21] . It was originally approved for the treatment of metastatic colorectal cancer, but was first used off-label in 2005 for the treatment of exudative age-related macular degeneration (AMD). Its off-label use has been expanded to treat macular edema due to venous occlusions, as well as DME. It is the most cost-effective anti-VEGF option [22] and hence the first option considered for many patients. The BOLT study was a randomized prospective clinical trial of 80 patients with center-involving DME who had received at least one prior laser treatment; subjects were randomly assigned to receive either 1.25 mg bevacizumab injections (3 initial injections every 6 weeks with possible further injections guided by an optical coherence tomography (OCT)-based protocol) or additional modified ETDRS macular laser therapy (examination every 4 months with re-treatment as warranted by ETDRS guidelines) [12] .
At 12 month follow up, the bevacizumab group had best-corrected visual acuity (BCVA) improve by a median of 8 ETDRS letters, compared to a loss of 0.5 letters in the laser group (p = 0.0002). The central subfield thickness (CSFT) improved by a mean of 129 μm, compared to only 68 μm in the laser group. Bevacizumab continued to show superior BCVA and anatomic results compared to laser at 24 month follow up, with the 6 bevacizumab group showing a mean gain of 8.6 letters versus loss of 0.5 letters for laser, and reduction of CSFT by 146 μm compared to only 118 μm for laser [13] .
The Pan-American Collaborative Retina Study Group retrospectively studied the efficacy of 1.25 mg vs 2.5 mg bevacizumab doses for diffuse DME. At 24 month follow up and after a mean of 5. 
Ranibizumab for DME
Ranibizumab, a smaller (48kDa) recombinant humanized monoclonal IgG1 antibody fragment (Fab), was specifically manufactured for use in the eye (unlike bevacizumab), and inhibits all known isoforms of VEGF-A. This molecule lacks a fragment crystallizable (Fc) region, which allows for faster systemic clearance [24] .
Ranibizumab was approved by the U.S. Food & Drug Administration (FDA) for DME in 2012, based on Genentech's Phase III trials, RIDE and RISE [25, 26] . These two identically-designed, parallel, double-masked, three-year clinical trials were shamtreatment controlled for 24 months. A total of 759 patients were randomized into three groups to receive monthly treatment with 0.3 mg ranibizumab (n=250), 0.5 mg ranibizumab (n=252) or sham injection (control group, n=257). Beginning at three months, macular laser rescue treatment was made available to all patients, if needed, based on pre-specified criteria. After month 24, patients in the sham injection group were eligible to receive monthly injections of 0.5 mg ranibizumab and all patients were followed and dosed monthly for a total of 36 months.
Compared to controls, a significantly greater percentage of ranibizumab-treated patients were able to read at least three additional lines (15 letters) at 24 months (primary endpoint). The number of ETDRS letters gained at 24 months follow up was 12.5, 11.9, and 2.6 in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, and sham groups, respectively (RISE). In RIDE, the number of letters gained was 10.9, 12, and 2.3 in the same order. month results indicate that patients in the sham group, who were eligible to cross over to monthly 0.5 mg ranibizumab after 24 months, did not achieve the same degree of VA gains as those patients who were in the ranibizumab group. After 12 months of ranibizumab, the crossover group only gained 2.8 letters compared to 10.6 and 11.1 letters in the 0.3 and 0.5 mg ranibizumab groups, respectively. This suggests that chronic macular edema may lead to a certain amount of irreversible VA loss, despite the fact that these patients CSFT improved by only 20 μm less than the ranibizumab group [25] .
The RESTORE study demonstrated superiority of ranibizumab alone or in combination with laser, compared to using laser monotherapy, as treatment options for DME. At 12 months, CSFT was reduced by 119 μm, 128 μm, and 61 μm in the ranibizumab monotherapy, ranibizumab + laser, and laser monotherapy groups, respectively (p<0.001). BCVA improved by 6.1, 5.8, and 0.9 letters in these groups by 12 months, respectively (p<0.0001). Visual acuity gains were associated with significant gains on the VFQ-25 scores [28] . Ranibizumab combined with prompt or deferred laser was also found to be superior to laser monotherapy in DRCR.net Protocol I [7] .
Aflibercept for DME
In 2014, aflibercept (also known as VEGF Trap-EYE) was approved for the treatment of DME. Aflibercept is a recombinant fusion protein that is composed of the second extracellular binding domain from human VEGFR-1 and the third binding domain fromVEGFR-2 fused to the Fc domain of human immunoglobulin G1 molecule; it inhibits VEGF-A, VEGF-B and placental growth factor (PlGF) [21] . Regeneron's Phase 3 VISTA-DME and VIVID-DME studies of 862 patients compared aflibercept 2 mg given monthly (2q4), aflibercept 2 mg given every two months (2q8 after five initial monthly injections), or macular laser photocoagulation (at baseline and then as needed) [29, 30] .
In the VISTA 52 week follow up, the 2q4 and 2q8 aflibercept dosing groups gained 12.5 and 10.7 ETDRS letters, respectively, compared to only 0.2 letters in the 9 laser group (p<0.0001). In VIVID, the 2q4 and 2q8 groups gained 10.5 and 10.7 letters versus only 1.2 letters in the laser group (p<0.0001). The anatomic reduction in CSFT was similar for both dosing regimens in VISTA: 186 μm (2q4) and 183 μm (2q8) compared to only 73 μm in laser. For VIVID, the difference between aflibercept and laser was even more pronounced, with 2q4 and 2q8 groups reducing CSFT by 195 μm and 192 μm, respectively, compared to only 66 μm for laser. Additional rescue laser was given to fewer eyes in the 2q4 and 2q8 groups (0.7% and 2.6% for VISTA and 4.4 and 8.1% for VIVID) compared to the laser group (31.2% for VISTA and 24.1% VIVID). A greater proportion of eyes in VISTA had previously received anti-VEGF injections (43% vs 9%)
The 100-week VIVID and VISTA results were recently published, and they report sustained superiority of aflibercept over laser. In VIVID, there were 11.5, 11.1, and 0.9 letter gains in the 2q4, 2q8, and laser groups, respectively. In VISTA, there were 11.4, 9.4, and 0.7 letter gains for the same groups [29] . The FDA-approved dosing for aflibercept is 2 mg every 2 months following 5 initial monthly injections. It also may be dosed once per month, but as the studies suggest, additional benefit was limited with this dosing plan. Analysis of eyes with CSFT reduction of <10% by week 12 indicated that these eyes generally underperformed compared to the entire cohort. By week 52, the 2q4, 2q8, and laser groups had gains of 8.2, 10.5, and -2.6 letters in VISTA, and 7.4, 10.9, and 0.8 letters in VIVID. The corresponding gains at week 100 were 6.6, 7.6, and -2.0 letters in VISTA, and 9.6, 8.1 and -0.1 letters in VIVID (Boyer DS, presented at Retina Society, Paris, France, October 8, 2015).
Comparing Anti-VEGF Options in DME
While the above mentioned studies show clear cut superiority of anti-VEGF treatments compared to laser for center-involving DME, there are not many large scale prospective studies comparing the efficacy of the anti-VEGFs to one another. On quick glance at the numbers reported in the aforementioned studies, it suggests that aflibercept and ranibizumab may be more effective than bevacizumab at reducing CSFT and improving BCVA. However, there are limitations in comparing numbers between separate studies with different treatment strategies and patient populations, especially given that the BOLT study was much smaller than RISE/RIDE and VIVID/VISTA. It is best to compare the anti-VEGF agents directly in a trial. to ranibizumab and bevacizumab for the treatment of DME in this study. Six hundred and sixty patients were randomized to receive either aflibercept 2 mg, bevacizumab 1.25 mg, or ranibizumab 0.3 mg dosed according to a protocol-specified algorithm. Anti-VEGF treatment within 12 months was exclusionary. Patients were treated with focal/grid laser at or after the 24 week visit if: 1) the OCT central subfield thickness was greater than or equal to 250 microns or there was edema that was threatening the fovea and 2) the eye did not improve on OCT or visual acuity from the last two consecutive injections [32] . bevacizumab; p = 0.036 for aflibercept vs. ranibizumab). These results held true regardless of initial baseline BCVA. The median number of injections using the protocolspecified retreatment regimen was one fewer in patients treated with aflibercept (9 injections) compared to bevacizumab and ranibizumab (10 injections each, p =0.045 for overall comparison). Fewer patients in the aflibercept group (37%) received criteriabased macular laser treatments than those treated with bevacizumab (56%) and ranibizumab (46%, p<0.001 for overall comparison) [32] . These results allow one to speculate that either aflibercept or ranibizumab would be of potential benefit for treating persistent DME after trial with bevacizumab, though one must keep in mind that the subjects had not received anti-VEGF injections for at least 12 months prior to the study.
Furthermore, the rates of most ocular and systemic adverse events (AEs) were similar across the three study groups. The rates of arterial thromboembolic events (ATE) as defined by the Anti-Platelet Trialists' Collaboration (non-fatal stroke, non-fatal myocardial infarction, and vascular death) in the trial were 3% in the aflibercept group, 4% in the bevacizumab group, and 5% in the ranibizumab group (p =0.56). There were more overall cardiovascular events in the ranibizumab group, compared to the aflibercept group and the bevacizumab group (p <0.01); this included more cardiac events and cerebrovascular events in the ranibizumab group [32] . A recent Cochrane review did not find any difference between bevacizumab and ranibizumab in terms of all-cause death, all serious systemic adverse events, ATE, myocardial infarction, or stroke. There was a higher incidence of gastrointestinal disorders associated with bevacizumab treatment (relative risk 1.82) [33].
Switching Anti-VEGF Therapy for Refractory DME
For DME patients who do not respond well to repeated injections of intravitreal bevacizumab, the clinician has the option to try other anti-VEGFs, corticosteroids, or macular laser. Evaluation with OCT may help identify other causes of macular edema, such as vitreomacular traction, which may warrant surgical treatment. Fluorescein angiogram can also be used adjunctively to identify focal areas of leakage from microaneursyms, which may be amenable to laser treatment. As of now, no large randomized prospective clinical trials comparing treatment regimens for refractory DME have been published, but several smaller uncontrolled studies can provide some insight.
The REEF study (12 month prospective nonrandomized trial of 43 patients) found benefit in switching from bevacizumab to three monthly injections of 0.5 mg ranibizumab in patients with residual macular edema (CSFT >300 μm). Prior to the switch, patients had been treated with a mean of 4.7 bevacizumab injections with mean CSFT of 500 μm. Switching to ranibizumab resulted in additional reduction of 113 μm and 165 μm at 3 and 6 month follow up, respectively, with gains of 6.6 and 8.8 letters of
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BCVA during the same time frames. Moreover, the 6/29 (20%) patients that did not respond adequately with ranibizumab 0.5 mg (CSFT reduction <10%) were switched to higher doses of three monthly 2.0 mg ranibizumab injections, which resulted in CSFT reduction >10% in 3 of 6 patients. Of note, the 2.0 mg dose of ranibizumab is not commercially available at this time [34] .
Ciulla et al perfomed a retrospective review of 33 eyes with refractory DME that had been previously received an average of 5.1 treatments, including bevacizumab, triamcinolone, or macular laser. Switching to ranibizumab resulted in a statistically significant improvement in CSFT (from 384 μm to 335 μm), and BCVA (from 20/100 to 20/90) after an average of 7 injections over 48 week follow up. Statistical significance was achieved in relation to number of days follow up, but not for number of ranibizumab injections [35] .
Lim et al performed a retrospective review of 21 eyes treated for DME that were unresponsive to either bevacizumab or ranibizumab (mean of 6 treatments), that were then converted to a median of 3 aflibercept injections and followed over a median of 5 months. CSFT improved significantly from 453 μm to 363 μm (-90 μm) after the first injection, and was 324 μm (-129 μm) at last follow up. BCVA improved significantly from logMAR 0.42 to 0.39 after one aflibercept, and then 0.37 logMAR at last follow up [36] . Wood et al reported that 11 of 14 (79%) eyes with persistent DME despite at least 3 injections of either bevacizumab or ranibizumab showed anatomic improvement after switching to aflibcercept; there was a 23% reduction of CSFT from 425 μm to 325 μm after 1 month (p<0.0132) [37] . Only 3 of 14 (21%) eyes had improved BCVA however.
Corticosteroids versus Anti-VEGF for DME
Chronic DME may differ even more in pathophysiology from non-chronic DME [38] . Anti-VEGF therapy may not be effective in all patients, because targeting VEGF does not suppress all the inflammatory cytokines and chemokines involved in DME.
More recently, there has been interest in intravitreal corticosteroids, as the dexamethasone intravitreal implant (DEX) [39] and the fluocinolone acetonide implant (FA) [40, 41] have been approved for the treatment of DME in 2014. There are few large prospective clinical trials comparing anti-VEGF agents to corticosteroids as first line therapy in center-involved DME, but DEX and FA implants could become early treatment for pseudophakic patients particularly. DRCR protocol I compared 0.5 mg ranibizumab to 4 mg intravitreal triamcinolone acetonide; when analysis was confined to the pseudophakic group of patients to control for the effect of cataract formation, the group that received intravitreal triamcinolone acetonide plus prompt laser showed similar visual acuity results to the group that received ranibizumab plus prompt laser, as both groups gained a mean of 8 letters by 12 month follow up. [42] .
In June 2014, the U.S. FDA approved a 0.7 mg dexamethasone implant (DEX) contained in a solid bioerodable polymer for the use in DME in pseudophakic patients or those phakic patients scheduled for cataract surgery. In September 2014, approval was expanded for the use in general DME patients, both pseudophakic and phakic, based on results of the MEAD study. After 3 years follow up, in which a mean of 4.1 DEX implants (0.7 mg) were administered, the DEX group experienced a mean CSFT reduction of 112 μm compared to 42 μm in the sham group. 22% of DEX 0.7 mg implant treated patients gained >15 letters BCVA compared to 12% in the sham group (p<0.108).
59% of the DEX 0.7 mg implant required cataract surgery compared to 7% in the sham group. 32% of the DEX group experienced IOP elevation ≥ 25 mmHg, 42% required IOP-lowering medications, and 0.6% required glaucoma incisional surgery [39] .
The BEVORDEX study was a randomized prospective trial comparing bevacizumab every 4 weeks to DEX every 16 weeks in 88 eyes with center-involving eyes with DME. At 12 months, 40% of bevacizumab-treated patients gained 10 or more letters of BCVA, compared to 41% in eyes that received DEX, although 11% of DEXtreated eyes lost 10 or more letters of BCVA due to cataract formation. The DEX implant resulted in greater reduction of CSFT (-187 μm) than bevacizumab (-122 μm). The DEX group also received fewer injections (2.7) than the bevacizumab group (8.6) over the course of 12 months [43] . Maturi et al. compared efficacy of combination therapy with DEX and bevacizumab vs. continued bevacizumab monotherapy in 40 eyes that had refractory DME after multiple bevacizumab injections. The combination group received bevacizumab at baseline, and then DEX at months 1, 5, and 9. They also received bevacizumab as needed for CSFT >250 or ETDRS VA less than 80 letters. After 12 months, compared to continued monthly bevacizumab monotherapy, the combination group had greater reduction of CSFT (-45 μm vs -30 μm, p =0.03), though VA improvement was not statistically significant for the combination group (combined group: +5.4 letters, bevacizumab: +4.9 letters, p=0.75). The combined group needed 3 fewer bevacizumab injections, though this was counterbalanced by the need for a mean of 2.1 DEX injections [44] .
A recent study compared the efficacy of fluocinolone acetonide (FA) sustained release implant in chronic (≥3 years duration) versus nonchronic (<3 years duration) DME, as part of a preplanned subgroup analysis of the FAME trial. The non-erodable FA implant releases the drug for up to 36 months. At month 36, the difference between FA implant and sham control in the percentage of subjects who gained 15 letters or more was significantly greater in 536 chronic DME subjects (34.0% vs. sham, 13.4%; P<0.001), compared to the 416 subjects with nonchronic DME (22.3% vs. sham, 27.8%; P = 0.275).
The differences could not be explained by baseline ocular characteristics, changes in anatomic features, or differences in re-treatment or ancillary therapies. The authors speculate that early DME is driven primarily by VEGF, while chronic DME may be driven more by inflammatory cytokines in addition to anatomic changes, and that intravitreal corticosteroids will inhibit the release of these inflammatory cytokines [38] .
The results suggest that the FA implant may be an option for patients who do not respond to other therapy. This report may also partially account for the clinical observations of beneficial effect using the DEX implant when anti-VEGF agents have minimal effect.
Corticosteroid-related side effects were noted in the FAME study. Incisional glaucoma surgery was required by 4.8% of patients in the 0.2 μg/day (low dose FA) group and 8.1% of patients in the 0.5 μg/day (high dose FA) group. Cataracts progressed in nearly all phakic eyes. In September 2014, the FDA approved FA implant containing 0.19 mg fluocinolone for DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. However, this previous course of corticosteroids was not specified. Clinicians could conceivably trial a topical corticosteroid, intravitreal bolus therapy with triamcinolone, or DEX implant.
Conclusion
In summary, anti-VEGF therapy is the new treatment of choice for centerinvolved DME, as many studies have shown that it is superior compared to macular laser photocoagulation. Bevacizumab continues to be the most widely utilized anti-VEGF agent due to its cost-effectiveness. Recent data suggests that aflibercept is the most potent anti-VEGF treatment for DME, particularly in patients with ETDRS BCVA worse than 20/40 [32] . Smaller studies have demonstrated anatomic and functional benefit in switching to ranibizumab [34] or aflibercept [36] when initial treatment with bevacizumab fails. Ongoing studies are exploring the efficacy of combining anti-VEGF treatment with sustained-release corticosteroids to treat DME.
Expert Opinion
Despite growing clinical research data to support the use of anti-VEGF agents to treat DME, numerous questions remain. Most clinicians do not follow dosing regimens employed in registration trials, as many will follow an off-label "treat and extend" regimen, which has not been studied in large randomized clinical trials. Furthermore, it is unclear if there is as much a need to "treat until absolutely dry" as in exudative AMD.
Many clinicians will switch between agents when there is suboptimal response; however, there is no consensus on the definition of suboptimal response or the definition of an appropriate trial of one agent before switching to another. One recent analysis of refractory DME cases from the VIVID/VISTA trials considered refractory DME to be <10% CSFT reduction after 12 weeks (Boyer DS, presented at Retina Society, Paris, France, October 8, 2015) . We believe that a 12-week time frame and minimum of 3 anti-VEGF injections is a reasonable cutoff for defining refractory DME.
There are multiple controversial issues surrounding bevacizumab and other agents. Proponents of bevacizumab cite large cost disparities between bevacizumab ($50), ranibizumab 0.3 mg ($1170) and aflibercept ($1850), while others note that patient assistance programs are readily available to assist underinsured patients and potentially limit financial risk for physician practices. Furthermore, bevacizumab is used off-label, as it is repackaged and resold by compounding pharmacies, around which there have been some sterility issues, leading to increased regulation and more laborious patientspecific bevacizumab prescription requirements. More recently, there has been cost profiling by insurance companies, which has likely led to the controversial narrowing of panels and/or being dropped by insurance networks. Finally, retina specialists assume public relations risk in being identified as a large consumer of Medicare funds, due in part to the expense of the FDA-approved anti-VEGF agents.
The protocol-based ETDRS visual acuity used in DRCR Protocol T is often several lines better than the Snellen BCVA routinely obtained in the clinical setting, so the 20/50 cut off for treating with aflibercept may not directly translate to clinical practice.
Adjusting for this, one may consider starting treatment with intravitreal bevacizumab for center-involved DME and only mild vision loss, especially when cost is an issue, as it has shown efficacy in reducing CSFT and improving BCVA. If CSFT or BCVA fails to improve after 2 bevacizumab injections, it may be prudent to switch to aflibercept or ranibizumab. One must also keep in mind that the strict monthly visits mandated in the clinical trials may not translate to clinical practice in the real world, where follow up may be less frequent and reliable, and with some patients being subsequently underdosed with anti-VEGF treatment.
While aflibercept was shown to be superior to ranibizumab in patients with ETDRS BCVA worse than 20/40 in DRCR Protocol T, these results may not apply to the population of refractory DME patients, whose pathophysiology could vary from those affected by treatment-naïve DME. As of now, one small retrospective series supports switching to aflibercept after patients have failed treatment with bevacizumab and ranibizumab, as it has been shown to result in statistically significant improvement in CSFT and BCVA [36] . Tachyphylaxis may partially explain the benefits achieved by switching from one anti-VEGF to another, as repeated doses of the same drug may result in diminishing effect. Larger prospective randomized clinical trials are needed to validate these findings. For those DME patients with ETDRS BCVA worse than 20/40, aflibercept is a first-line option, but its high cost continues to be a limiting factor for many patients despite the advantages of its 2-month injection frequency.
For non-centered involved refractory DME, laser treatment could remain an effective treatment, since the risks of laser photocoagulation are minimal in these cases, compared to the risks, discomfort, and expense of intravitreal therapies. After a series of anti-VEGF injections, a deferred focal laser therapy to localized areas of microaneurysm formation may decrease the number of required subsequent injections. For centerinvolved DME that is persistent despite periodic anti-VEGF therapy, the durable action of corticosteroid implants, such as the DEX and FA implants, facilitates combination therapy. The risks of sustained corticosteroid therapy, mainly glaucoma and cataract progression, should be carefully considered in the context of each patient. Pseudophakic patients, and those who have used a trial of corticosteroids without ocular hypertension, are preferred candidates for the DEX and FA implants.
Although the improvement in visual acuity and CSFT may seem modest after switching therapies, these cases of refractory DME can be especially difficult to treat, and consequently these modest improvements can be clinically meaningful, especially in patients with bilateral refractory DME. Bevacizumab, ranibizumab, and aflibercept each have different molecular sizes, binding affinities for VEGF, as well as different half-lives in the vitreous, and this could account for some of the differences noted between these agents. Aflibercept is the only available treatment that targets placental growth factor, which has an unclear role in the pathogenesis of DR, but animal studies suggest that it may contribute to blood-retinal barrier breakdown [45, 46] .
Combining anti-VEGF treatment with sustained-release corticosteroids is a promising area of future research, as this approach may allow for more extensive control of the complex inflammatory pathways involved in DME. The synergistic effect of sustained-release corticosteroids may result in fewer anti-VEGF injections needed to keep DME under control. Currently, the DRCR Protocol U is exploring the efficacy of combination therapy with 0.3 mg ranibizumab and dexamethasone intravitreal implant compared to continued therapy with 0.3 mg ranibizumab to treat persistent DME. The results of DRCR Protocol T suggest the need for large prospective randomized trials to validate that switching from either bevacizumab to ranibizumab or aflibercept is superior to continued bevacizumab treatment in cases of persistent DME. Further study of refractory DME is warranted, given the visual disability caused.
Article Highlights Box
• The complex pathophysiology of DME involves upregulation of VEGF and other 21 inflammatory mediators.
• Anti-VEGF agents are first-line treatment for center-involved DME.
Bevacizumab is a cost-effective and widely used anti-VEGF treatment, though aflibercept is the most effective option in patients with BCVA worse than 20/40 using ETDRS protocol eye charts.
• Some cases of DME are refractory to multiple bevacizumab treatments, and small studies report that switching to ranibizumab or aflibercept results in additional improvement in BCVA and macular thickness
• Future research will focus on efficacy of combined anti-VEGF and sustainedrelease corticosteroids to control refractory DME
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